Evidence map›Paper›PMID 42751445›Full record

ReviewAmerican heart journal plus : cardiology research and practice2026

From snapshot to trajectory: A multimodality right-heart monitoring framework across the heart failure spectrum.

Arif Albulushi, Mohammed Al Habsi, Amira Al-Kharusi

Abstract readReview
In one paragraph

Review in American heart journal plus : cardiology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Arif AlbulushiDepartment of Adult Cardiology, National Heart Center, The Royal Hospital, Muscat, Oman.
Mohammed Al HabsiDepartment of Adult Cardiology, National Heart Center, The Royal Hospital, Muscat, Oman.
Amira Al-KharusiDepartment of National Diabetes and Endocrine Centre, The Royal Hospital, Muscat, Oman.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Right ventricular (RV) dysfunction, pulmonary vascular load, tricuspid regurgitation, and venous congestion are important determinants of symptoms and outcomes across the heart failure spectrum, yet longitudinal follow-up remains predominantly left ventricle-centered. This narrative review summarizes the physiological and multimodality imaging basis for serial right-heart assessment across HFrEF, HFmrEF, and HFpEF, using SGLT2 inhibition and dapagliflozin as a contemporary mechanistic example rather than the basis for a drug-specific monitoring algorithm. We propose a pragmatic, therapy-agnostic trajectory framework integrating clinical status, biomarkers, echocardiography, cardiac magnetic resonance, and selective invasive hemodynamics. The approach distinguishes RV dysfunction from overt right-heart failure, incorporates loading conditions, rhythm and tricuspid regurgitation phenotype, and prioritizes serial direction of change over isolated measurements. Emerging SGLT2 inhibitor data provide signals of favorable hemodynamic and RV-pulmonary arterial interaction in selected populations, although dedicated RV-focused randomized evidence remains limited. Suggested reassessment windows are illustrative rather than validated and should be individualized. This framework is intended to complement conventional heart failure assessment and support selective advanced imaging or hemodynamic clarification when clinical and right-heart trajectories are discordant.

Indexed as

Heart failureHemodynamicsMultimodality imagingPulmonary hypertensionRight ventricleRV–PA couplingSGLT2 inhibitors

Identifiers

PMID42751445
PMCPMC13579682

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.